menu
    • menu
    [{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ANK-700","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"ANK-700","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Kanyos Bio"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ANK-700","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Anokion SA

    Menu

    Anokion SA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anokion Announces Positive Phase 2 Data for KAN-101 in Celiac Disease

                            Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.

                            Product Name : KAN-101

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 08, 2025

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces Early Completion of Enrollment in KAN-101 Trials for Celiac Disease

                            Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            December 19, 2024

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANK-700

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Supports ANK-700 as Potential Treatment for Relapsing-Remitting MS

                            Details : Anokion's ANK-700 is being assessed as a potential disease-modifying treatment for patients with relapsing-remitting multiple sclerosis.

                            Product Name : ANK-700

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2024

                            Lead Product(s) : ANK-700

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces New Clinical Data of KAN-101 for the Treatment of Celiac Disease

                            Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.

                            Product Name : KAN-101

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            May 20, 2024

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces Clinical Progress with KAN-101 and ANK-700

                            Details : KAN-101 is a novel immune tolerance therapy, which encompasses an established gluten antigen delivered to the liver and immune system using the company’s proprietary liver-targeting technology.

                            Product Name : KAN-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 12, 2023

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modi...

                            Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.

                            Product Name : KAN-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 09, 2023

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline

                            Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.

                            Product Name : KAN-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 27, 2022

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for ...

                            Details : KAN-101 is an investigational therapy being evaluated as a treatment for individuals with celiac disease, a serious autoimmune disease triggered by ingestion of gluten, for which there are no approved therapeutic treatments available.

                            Product Name : KAN-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 21, 2022

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Anokion Announces $35 Million Equity Investment from Pfizer

                            Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.

                            Product Name : KAN-101

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2022

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : $35.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed

                            Anokion SA

                            Switzerland arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Anokion Announces $35 Million Equity Investment from Pfizer

                            Details : Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.

                            Product Name : KAN-101

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2022

                            Lead Product(s) : KAN-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth